Interestingly, gene set enrichment analysis (GSEA) of 794 differentially hydroxymethylated genes (differential 5hmC) identified in cfDNA from patients with PDA demonstrated a similar genetic pattern to those commonly dysregulated after KRAS activation and TP53 inhibition in primary tumor tissue [43]. This evidence concerns the gene KRAS and Patent ductus arteriosus.